Literature DB >> 2266401

Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats.

M J Abrams1, M Juweid, C I tenKate, D A Schwartz, M M Hauser, F E Gaul, A J Fuccello, R H Rubin, H W Strauss, A J Fischman.   

Abstract

The biologic behavior of human polyclonal immunoglobulin (IgG) radiolabeled with technetium-99m (99mTc) by a novel method, via a nicotinyl hydrazine derivative, was evaluated in rats. Technetium-99m- and indium-111-IgG were co-administered to normal rats and biodistribution was determined at 2, 6, and 16 hr. The inflammation imaging properties of the two reagents were compared in rats with deep-thigh infection due to Escherichia coli. Blood clearance of both antibody preparations was well described by a bi-exponential function: (99mTc-IgG: t1/2 = 3.82 +/- 0.89 and 57.52 +/- 1.70 hr. 111In-IgG: 3.93 +/- 0.117 and 40.71 +/- 1.26 hr). Biodistributions in the solid organs were similar, however, small but statistically significant differences were detected: 99mTc-IgG greater than 111In-IgG in lung, liver, and spleen; 99mTc-IgG less than 111In-IgG in kidney and skeletal muscle (p less than 0.01). At all three imaging times, target-to-background ratio and percent residual activity for the two compounds were remarkably similar. These studies establish that human polyclonal IgG labeled with 99mTc via a nicotinyl hydrazine modified intermediate is equivalent to 111In-IgG for imaging focal sites of infection in experimental animals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2266401

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  56 in total

Review 1.  Apoptosis-detecting radioligands: current state of the art and future perspectives.

Authors:  Christophe M M Lahorte; Jean-Luc Vanderheyden; Neil Steinmetz; Christophe Van de Wiele; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-12       Impact factor: 9.236

2.  Syntheses and structural characterization of rhenium-bis-hydrazinopyrimidine core complexes with thiolate and Schiff base coligands.

Authors:  Frank J Femia; Xiaoyuan Chen; Kevin P Maresca; John W Babich; Jon Zubieta
Journal:  Inorganica Chim Acta       Date:  2000-12-15       Impact factor: 2.545

3.  (99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging.

Authors:  María Fernanda García; Xiuli Zhang; Manankumar Shah; Jessica Newton-Northup; Pablo Cabral; Hugo Cerecetto; Thomas Quinn
Journal:  Bioorg Med Chem       Date:  2016-01-29       Impact factor: 3.641

4.  Accumulation of immunoglobulin G at focal sites of inflammation.

Authors:  M Juweid; H W Strauss; H Yaoita; R H Rubin; A J Fischman
Journal:  Eur J Nucl Med       Date:  1992

5.  Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Hyunki Kim; Karri D Folks; Lingling Guo; Jeffery C Sellers; Naomi S Fineberg; Cecil R Stockard; William E Grizzle; Donald J Buchsbaum; Desiree E Morgan; James F George; Kurt R Zinn
Journal:  Mol Imaging       Date:  2011-06       Impact factor: 4.488

6.  A novel ternary ligand system useful for preparation of cationic (99m)Tc-diazenido complexes and (99m)Tc-labeling of small biomolecules.

Authors:  Young-Seung Kim; Zhengjie He; Wen-Yuan Hsieh; Shuang Liu
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

Review 7.  Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Anticancer Agents Med Chem       Date:  2007-05       Impact factor: 2.505

Review 8.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

9.  How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.

Authors:  Robert C King; M Bashir-Uddin Surfraz; Stefano C G Biagini; Philip J Blower; Stephen J Mather
Journal:  Dalton Trans       Date:  2007-09-25       Impact factor: 4.390

10.  Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

Authors:  Patsy G Oliver; Albert F LoBuglio; Kurt R Zinn; Hyunki Kim; Li Nan; Tong Zhou; Wenquan Wang; Donald J Buchsbaum
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.